- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07780383
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: First line of the email MUST contain NCT # and Site #.
Sauvegarde des contacts de l'étude
- Nom: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Numéro de téléphone: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Lieux d'étude
-
-
California
-
Anaheim, California, États-Unis, 92801
- Recrutement
- CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
-
Contact:
- Amina Haggag, Site 0001
- Numéro de téléphone: 714-774-7777
-
-
Florida
-
Bradenton, Florida, États-Unis, 34205
- Pas encore de recrutement
- Local Institution - 0003
-
Contact:
- Site 0003
-
Daytona Beach, Florida, États-Unis, 32117
- Pas encore de recrutement
- Local Institution - 0005
-
Contact:
- Site 0005
-
Naples, Florida, États-Unis, 34105
- Pas encore de recrutement
- Local Institution - 0007
-
Contact:
- Site 0007
-
The Villages, Florida, États-Unis, 32162
- Pas encore de recrutement
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
Georgia
-
Decatur, Georgia, États-Unis, 30030
- Pas encore de recrutement
- Local Institution - 0004
-
Contact:
- Site 0004
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Participants must have a BMI of 18.0 to 35.0 kg/m2.
- For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
- For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
- For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).
- For Part C: Participants must have evidence of positive plasma pTau217.
Exclusion Criteria
- For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
- For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
- For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
- For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Panel A1: BMS986446
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Panel A2: BMS986446
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Panel A3: BMS986446
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Panel B1: BMS986446
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Panel B2: BMS986446
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Panel C1: BMS986446
|
Specified dose on specified days
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Maximum observed concentration (Cmax)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Time of maximum observed concentration (Tmax)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
AUC(INF)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Half-life (T-HALF)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent total body clearance in SC administration (CLT/F)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Total body clearance in IV infusion (CLT)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent volume of distribution of terminal phase in SC administration (Vz/F)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Volume of distribution of terminal phase (VZ)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse events (AEs)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Serious adverse events (SAEs)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
AEs reported as related to BMS-986446
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Incidence of anti-drug antibody (ADA)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for Cmax
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for Cmax
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for AUC
Délai: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Local tolerance evaluation
Délai: Up to approximately 5 months
|
This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location. |
Up to approximately 5 months
|
|
Cmax
Délai: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Tmax
Délai: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
AUC(0-T)
Délai: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(0-672)
Délai: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(INF)
Délai: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
T-HALF
Délai: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
CLT/F
Délai: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Vz/F
Délai: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Trough observed plasma concentration (Ctrough)
Délai: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Concentration at the end of a dosing interval (Ctau)
Délai: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Area under the concentration-time curve within a dosing interval (AUC(TAU))
Délai: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CN008-0028
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Délai de partage IPD
See Plan Description
Critères d'accès au partage IPD
See Plan Description
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .